Targeting the PD-1 pathway: a new hope for gastrointestinal cancers

References

• Howlader N, Noone AM, Krapcho M, Miller D, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Tepper JE, Venook AP. Special series: advances in GI cancer. J Clin Oncol 2015;33:1717-20
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39
   PubMed Web of Science ®Google Scholar
• Kroeker RM, McVeigh ER, Hardy P, et al. In vivo measurements of NMR relaxation times. Magn Reson Med 1985;2:1-13
   PubMed Web of Science ®Google Scholar
• Wang J, Reiss KA, Khatri R, et al. Immune therapy in GI malignancies: a review. J Clin Oncol 2015;33:1745-53
   PubMed Web of Science ®Google Scholar
• Jacobs J, Smits E, Lardon F, et al. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect. J Immunol Res 2015;2015:158038
   PubMed Web of Science ®Google Scholar
• Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy 2014;6:459-75
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002;169:5538-45
   PubMed Web of Science ®Google Scholar
• Eppihimer MJ, Gunn J, Freeman GJ, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002;9:133-45
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Canc Res 2014;20:5064-74
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Sun H, Liao X, et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Canc Immunol Res 2015;3:1308-15
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016: published online 8 October 2016. doi no: 10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Canc Treat Rev 2015;41:868-76
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86
   PubMed Web of Science ®Google Scholar
• Yazici O, Sendur MA, Ozdemir N, Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016;22:471-89
   PubMed Web of Science ®Google Scholar
• Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochemica 2006;108:19-24
   PubMed Web of Science ®Google Scholar
• Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 2014;96:284-91
   PubMed Web of Science ®Google Scholar
• Wang W, Sun J, Li F, et al. A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Human Mutation 2012;33:480-4
   PubMed Web of Science ®Google Scholar
• Eto S, Yoshikawa K, Nishi M, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer 2016;19:466-71
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhu Y, Wu C, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Canc Immunol Immunother 2010;59:1707-14
   PubMed Web of Science ®Google Scholar
• Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016: published online 18 March 2016. doi no: 10.18632/oncotarget.8169
   Web of Science ®Google Scholar
• Lin SJ, Gagnon-Bartsch JA, Tan IB, et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut 2015;64:1721-31
   PubMed Web of Science ®Google Scholar
• Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Canc Res 2014;26:104-11
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Canc Res 2005;11:2947-53
   Web of Science ®Google Scholar
• Derks S, Nason KS, Liao X, et al. Epithelial PD-L2 expression marks Barrett’s esophagus and esophageal adenocarcinoma. Canc Immunol Res 2015;3:1123-9
   PubMed Web of Science ®Google Scholar
• Doi TP-PS, Jalal SI, Mai-Dang H, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: preliminary results from KEYNOTE-028. ASCO Annual Meeting Abstracts (4010) 2015
   Google Scholar
• Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget 2016;7(17):24269-83
   PubMed Web of Science ®Google Scholar
• Segal NH, Hwu WJ, Massard C, et al. A phase 1 multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data. The European Society for Medical Oncology (ESMO) Meeting, Madrid, Spain, 2014
   Google Scholar
• Kelly K, Infante JR, Iannotti N, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. ASCO Annual Meeting Abstracts (3044) 2015
   Google Scholar
• Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944-51
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Canc Res 2013;19:462-8
   PubMed Web of Science ®Google Scholar
• Study of ONO-4538 in Gastric Cancer. ClinicalTrials.gov identifier: NCT02746796. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer. ClinicalTrials.gov identifier: NCT02267343. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors. ClinicalTrials.gov identifier: NCT01928394. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors. ClinicalTrials.gov identifier: NCT02488759. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Study of ONO-4538 in Unresectable Advanced or Recurrent Esophageal Cancer. ClinicalTrials.gov identifier: NCT02569242. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer. ClinicalTrials.gov identifier: NCT02318901. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061). ClinicalTrials.gov identifier: NCT02370498. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059). ClinicalTrials.gov identifier: NCT02335411. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer. ClinicalTrials.gov identifier: NCT02901301. Available at: www.clinicaltrials.gov [Last accessed 6 December 2016]
   Google Scholar
• Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062). ClinicalTrials.gov identifier: NCT02494583. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery ClinicalTrials.gov identifier: NCT02730546. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180). ClinicalTrials.gov identifier: NCT02559687. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Study of Pembrolizumab (MK-3475) Versus Investigator’s Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181). ClinicalTrials.gov identifier: NCT02564263. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma. ClinicalTrials.gov identifier: NCT02340975. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM). ClinicalTrials.gov identifier: NCT02678182. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Study of Durvalumab (MEDI4736) in Esophageal Cancer. ClinicalTrials.gov identifier: NCT02639065. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Adjuvant Durvalumab for Esophageal Cancer. ClinicalTrials.gov identifier: NCT02520453. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov identifier: NCT01375842. Available at: www.clinicaltrials.gov [Last accessed 15 June 2016]
   Google Scholar
• Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep 2015;3:289-97
   Google Scholar
• Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014;25:1032-8
   PubMed Web of Science ®Google Scholar
• Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322-30
   PubMed Web of Science ®Google Scholar
• Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Canc Discov 2015;5:16-18
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Canc Discov 2015;5:43-51
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20
   PubMed Web of Science ®Google Scholar
• Le DTUJ, Wang H, Bartlett BR, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. ASCO Annual Meeting Abstracts (103) 2016
   Google Scholar
• George TJFG, Sun J, Gowen K, et al. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer. ASCO Annual Meeting Abstracts (3587) 2016
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34
   PubMed Web of Science ®Google Scholar
• A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer. ClinicalTrials.gov identifier: NCT02860546. Available at: www.clinicaltrials.gov [Last accessed 6 December 2016]
   Google Scholar
• A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142). ClinicalTrials.gov identifier: NCT02060188. Available at: www.clinicaltrials.gov [Last accessed 21 June 2016]
   Google Scholar
• Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer. ClinicalTrials.gov identifier: NCT02375672. Available at: www.clinicaltrials.gov [Last accessed 21 June 2016]
   Google Scholar
• Study of Pembrolizumab (MK-3475) as Monotherapy in Participants with Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164). ClinicalTrials.gov identifier: NCT02460198. Available at: www.clinicaltrials.gov [Last accessed 21 June 2016]
   Google Scholar
• Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177). ClinicalTrials.gov identifier: NCT02563002. Available at: www.clinicaltrials.gov [Last accessed 21 June 2016]
   Google Scholar
• A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors. ClinicalTrials.gov identifier: NCT02669914. Available at: www.clinicaltrials.gov [Last accessed 6 December 2016]
   Google Scholar
• Verslype C, Rosmorduc O, Rougier P, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii41-8
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017:389(10064):56-66
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015;33(Suppl):abstr LBA101
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau TC, et al. Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of the CheckMate-040 dose escalation study. J Clin Oncol 2016;34(Suppl):abstr 4012
   Google Scholar
• Sangro B, Melero I, Yau TC, et al. Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study. J Clin Oncol 2016;34(Suppl):abstr 4078
   Google Scholar
• Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer 2016;6:1-12
   PubMed Web of Science ®Google Scholar